Table 1 Participants’ characteristics depending on the baseline CL group
From: Amyloid-PET imaging predicts functional decline in clinically normal individuals
Total N = 1260 | Aβ- (CL < 12) N = 765 | Aβ±  (12 ≤ CL ≤ 50) N = 301 | Aβ+  (CL > 50) N = 194 | p | Post-Hoc | |||
|---|---|---|---|---|---|---|---|---|
Median | Q1 – Q3 | Median | Q1 – Q3 | Median | Q1 – Q3 |  |  | |
Baseline age (years) | 66.0 | 61.0 – 71.0 | 69.0 | 64.0 – 75.0 | 73.0 | 68.0 – 78.0 |  < .001 | Aβ- < Aβ±  < Aβ+ |
Sex (% females/males) | 59/41% | 53/47% | 53/47% | .084 | – | |||
Education (years) | 15.0 | 12.0 – 17.0 | 15.0 | 12.0 – 17.0 | 14.0 | 12.0 – 17.0 | .194 | – |
APOE ε4 carriers (%Yes/No/Missing) | 30/70/0% | 46/53/1% | 68/29/3% |  < .001 | Aβ- < Aβ±  < Aβ+ | |||
Baseline MMSE (/30) | 29.0 | 29.0 – 30.0 | 29.0 | 28.0 – 30.0 | 28.0 | 27.0 – 30.0 |  < .001 | Aβ+ < Aβ± ≈ Aβ-* |
Baseline Global-CDR (% CDR = 0/CDR = 0.5) | 87/13% | 82/18% | 59/41% |  < .001 | Aβ+ ≠ Aβ± ≈ Aβ- | |||